This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Homology Medicines (FIXX) Looks Good: Stock Adds 8% in Session
by Zacks Equity Research
Homology Medicines (FIXX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Biomarin to File Regulatory Applications for Vosoritide in Q3
by Zacks Equity Research
BioMarin (BMRN) plans to file regulatory applications seeking approval for its achondroplasia candidate, vosoritide, in the third quarter of 2020.
Is Homology Medicines (FIXX) Stock a Solid Choice Right Now?
by Zacks Equity Research
Homology Medicines (FIXX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
Homology Medicines (FIXX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Homology Medicines (FIXX) delivered earnings and revenue surprises of 23.61% and 40.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Homology Medicines (FIXX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin to Begin Early-Stage Study on Gene Therapy for PKU
by Zacks Equity Research
BioMarin (BMRN) is set to initiate dosing in an early-stage clinical study in the first quarter to evaluate its gene therapy candidate, BMN 307, in phenylketonuria, a rare disease affecting the brain.
Homology Medicines (FIXX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Homology Medicines (FIXX) delivered earnings and revenue surprises of -15.52% and 17.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Homology Medicines (FIXX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Homology Medicines (FIXX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Homology Medicines (FIXX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Homology Medicines (FIXX) delivered earnings and revenue surprises of -16.36% and -73.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?